Elixir Pharmaceuticals Announces New Data at the 2008 American Diabetes Association Annual Meeting
Published: Jun 09, 2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., today announced new data validating ghrelin, a potent, naturally occurring hormone, as a master regulator of metabolism. The data provides the most advanced evidence to date of the array of metabolic improvements in mice genetically engineered to lack the receptor for ghrelin (“knockout” mice). In particular, the results demonstrated organ-specific improvements that ultimately may have an impact in the treatment of type 2 diabetes and other widespread metabolic diseases.